ASCO 2022 | Impact of intensive multimodal treatment on outcomes in anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare and aggressive type of thyroid malignancy associated with poor prognosis and outcomes. Firas Baidoun, MD, Cleveland Clinic, Cleveland, OH, discusses the findings of a retrospective analysis evaluating the impact of intensive multimodal treatment on the outcomes of patients with anaplastic thyroid cancer using the National Cancer Database. Patients with anaplastic thyroid cancer who were treated with intensive multimodal therapy had statistically significant improvement in overall survival compared to patients who received less intense therapy. This survival benefit was observed in both metastatic and non-metastatic groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.